On October 17, 2023 Flamingo Therapeutics ("Flamingo") reported the presentation of a "Trials-in-Progress", or TiP, poster at the ESMO (Free ESMO Whitepaper) Congress 2023, taking place October 20-24, 2023, in Madrid, Spain (Press release, Flamingo Therapeutics, OCT 17, 2023, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-poster-presentation-at-esmo-congress-2023 [SID1234636063]). Members of the Flamingo leadership team, Andrew Denker, MD, PhD, Chief Medical Officer, and Morgane Perdomini, PhD, Director Development, will be present at the congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the TiP poster presentation are below:
Title: "PEMDA-HN, an Open-Label, Phase II, Randomized Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)"
Presentation #: 943 TiP
Date: Sunday, October 22, 2023
Presenting Author: Nabil F. Saba (Atlanta, United States of America)
More details can be found on the ESMO (Free ESMO Whitepaper) website.